A key finding from preclinical AD models is that cellular-level changes associated with tau and Aβ produces a combined functional consequence of altered excitatory–inhibitory balance in neural networks (Palop and Mucke, 2016; Harris et al., 2020; Chang et al., 2021; Maestú et al., 2021). This evidence concerns the gene MAPT and Alzheimer disease.